PATENT CLAIM ANALYSIS

Application Number: 16364577
Application Type: Utility
Filing Date: 2019-03
Publication Date: 2019-09
Patent Classification: ["424", "001890"]

Abstract:
Disclosed herein, inter alia, are prodrug compositions and methods of using the same for treatment and detection of disease. Specifically, disclosed herein is a compound of formula (I) having spiro-fused 1,2,4-trioxolane and piperidine rings, namely, 1,2,4-trioxa-8-azaspiro[4.5]decane. Also disclosed is a pharmaceutical composition containing the compound and a pharmaceutically acceptable carrier.

Claim (Index 50):
A compound having the formula: wherein\n -L 1 -R 1  is \u2014H; \n L 2 , L 3 , L 4 , L 6 , L 7 , L 8 , and L 9  are each a bond; \n R 2 , R 3 , R 4 , R 6 , R 7 , R 8 , and R 9  are each hydrogen; \n L 10  is \u2014CH 2 \u2014; \n L 5  is independently selected from a bond, \u2014N(R 17 )\u2014, \u2014N(R 17 )C(O)O\u2014, \u2014O\u2014, \u2014S\u2014, \u2014OC(O)\u2014, \u2014OC(O)N(R 17 )\u2014, \u2014OC(O)O\u2014, \u2014OSO 2 \u2014, \u2014C(O)N(R 17 )\u2014, \u2014N(R 17 )C(O)\u2014, \u2014S(O) 2 N(R 17 )\u2014, \u2014N(R 17 )S(O) 2 \u2014, substituted or unsubstituted alkylene, substituted or unsubstituted heteroalkylene, substituted or unsubstituted cycloalkylene, substituted or unsubstituted heterocycloalkylene, substituted or unsubstituted arylene, or substituted or unsubstituted heteroarylene; \n R 17  is independently hydrogen, halogen, \u2014CF 3 , \u2014CN, \u2014OH, \u2014NH 2 , \u2014COOH, \u2014CONH 2 , \u2014NO 2 , \u2014SH, \u2014SO 2 Cl, \u2014SO 3 H, \u2014SO 4 H, \u2014SO 2 NH 2 , \u2014NHNH 2 , \u2014ONH 2 , \u2014NHC\u2550(O)NHNH 2 , \u2014NHC\u2550(O)NH 2 , \u2014NHSO 2 H, \u2014NHC\u2550(O)H, \u2014NHC(O)\u2014OH, \u2014NHOH, \u2014OCF 3 , \u2014OCHF 2 , substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; and \n R 5  is independently a monovalent form of GDC-0973, a monovalent form of selumetinib, a monovalent form of ARRY-162,

Metadata:
- Claim Count in Document: 35.0
- Percentile: 99.0
- Lexical Diversity: 1.3913
- Patent Class: 424.0
- Transitional Phrase Type: none
- Component Type: 0
- Foreign Priority: False
- Related Applications: ['15118268', '15382942', '14670088', '15531245', '15778213']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7639842969068413
- 35 USC 102 Novelty (BERT): 0.5418927526261366
- Combined Prediction Score: 0.7417751424787709
- Mean Citation Score: 302.909626
- Max Citation Score: 371.87717
- Similarity Product: 305.6345009916985

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 1
- Claim Label 112: 0
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test